MWNA
TPTX

Marshall Wace North America’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Marshall Wace North America’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-30,942
Closed -$1.26M – 1633
2019
Q2 		$1.26M Buy
+30,942
New +$1.1M 0.01% 686

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Marshall Wace North America's TPTX Position: Q3 2019 in Review

Marshall Wace North America sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2019, closing a stake of 30,942 shares — an estimated $1.26M sold.

Marshall Wace North America first reported a position in TPTX in Q2 2019 and held it in 1 quarter. The position peaked at $1.26M in Q2 2019. 98 funds tracked by Wall St. Rank hold TPTX as of Q3 2019.

  • Marshall Wace North America reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Marshall Wace North America sold 30,942 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $1.26M.
  • Marshall Wace North America first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Marshall Wace North America's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.26M in Q2 2019.
  • 98 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Marshall Wace North America's 13F filing for Q3 2019, filed 14 Nov 2019.